Angiogenesis and osteopontin expression in paraskeletal myeloma with plasmablastic morphology and aggressive clinical course: a report of two cases

Abstract

Extramedullary disease (EMD) of multiple myeloma (MM) can present as paraskeletal (paraosseous) plasmocytoma (PP) that arise from skeletal focal lesions or extramedullary plasmacytomas (EMP) that derive from hematogenous spread. The pathogenetic mechanisms that distinguish classical MM, PP, and EMP are still insufficiently known, as are the therapies that would be effective in EMD. The aim of this study was to evaluate immunohistochemically the angiogenesis, determined as microvessel density (MVD) and osteopontin expression in PP, of two patients with MM of plasmablastic morphology and an aggressive course of disease. We found high levels of MVD and osteopontin expression in both cases of PP. The role of angiogenesis and osteopontin in EMD should be clarified in future investigations, especially since there are no satisfactory therapeutic protocols for this form of multiple myeloma, and both of these biological factors can be the potential targets of new therapies.

Keywords

Extramedullary myeloma / paraskeletal plasmacytoma / osteopontin / angiogenesis / plasmablastic morphology

References

[1] Bansal R,Kumar S.Extramedullary disease in multiple myeloma.Blood Cancer J2021;11:161 PMCID:PMC8481260

[2] He J,He D.Multiple extramedullary-bone related and/or extramedullary extraosseous are independent poor prognostic factors in patients with newly diagnosed multiple myeloma.Front Oncol2021;11:668099 PMCID:PMC8295340

[3] Beksac M,Kanellias N.A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma study group and barcelona university: analysis of parameters that improve outcome.Haematologica2020;105:201-8 PMCID:PMC8018150

[4] Ribatti D.New insights in anti-angiogenesis in multiple myeloma.Int J Mol Sci2018;19:2031 PMCID:PMC6073492

[5] Ribatti D,Vacca A.Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma.Oncogene2006;25:4257-66

[6] Bastos ACSF,Emerenciano M.Osteopontin and their roles in hematological malignancies: splice variants on the new avenues.Cancer Lett2017;408:138-43

[7] Duletić-Načinović A,Valković T.Concurrent elevations of VEGF, osteopontin and MCP-1 serum levels are independent predictors of survival in patients with diffuse large B-cell lymphoma.Acta Haematol2016;136:52-61

[8] Valković T,Lučin K.Plasma levels of osteopontin and vascular endothelial growth factor in association with clinical features and parameters of tumor burden in patients with multiple myeloma.Biomed Res Int2014;2014:513170 PMCID:PMC4065766

[9] Saeki Y,Ishii T.Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications.Br J Haematol2003;123:263-70

[10] Gagelmann N,Iacobelli S.Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the chronic malignancies working party of the EBMT.Haematologica2018;103:890-7 PMCID:PMC5927971

[11] Varettoni M,Pica G,Pascutto C.Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients.Ann Oncol2010;21:325-30

[12] Pour L,Greslikova H.Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.Haematologica2014;99:360-4 PMCID:PMC3912968

[13] Pasmantier MW.Extraskeletal spread in multiple plasma cell myeloma: a review of 57 autopsied cases.Cancer1969;23:167-74

[14] Deng S,An G.Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.Clin Lymphoma Myeloma Leuk2015;15:286-91

[15] Mulligan G,Di Bacco A.Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.Blood2014;123:632-9 PMCID:PMC4123425

[16] Varga C,Laubach J.Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.Br J Haematol2015;169:843-50

[17] Roccaro AM,Sacco A.CXCR4 Regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation.Cell Rep2015;12:622-35 PMCID:PMC4961259

[18] Azab AK,Azab F.P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.Blood2012;119:1468-78 PMCID:PMC3286211

[19] Dahl IM,Kauric G.Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma.Br J Haematol2002;116:273-7

[20] Hedvat CV,Teruya-Feldstein J.Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma.Br J Haematol2003;122:728-44

[21] Montefusco V,Spada S.Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.Haematologica2020;105:193-200 PMCID:PMC6939525

[22] Mangiacavalli S,Ferretti V.The possible role of burden of therapy on the risk of myeloma extramedullary spread.Ann Hematol2017;96:73-80

[23] Sfiridaki A,Pappa C.Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma.J Hematol Oncol2011;4:22 PMCID:PMC3102033

[24] Cerny J,Hutchinson L.Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma.Eur J Haematol2008;81:65-9

[25] Kumar S,Dispenzieri A.Prognostic value of angiogenesis in solitary bone plasmacytoma.Blood2003;101:1715-7